Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Approximately Half of People with Diabetes Worldwide Do Not Know They Have the Disease
Approximately Half of People with Diabetes Worldwide Do Not Know They Have the Disease: GBD Analysis

September 10th 2025

Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

September 2nd 2025

More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose / image credit: ©New Africa/AdobeStock
More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose

September 1st 2025

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

August 26th 2025

What Do Individuals With Obesity Want in am "Ideal" Primary Care Visit? image credit ©Coloures-Pic/stock.adobe.com
What Do Individuals With Obesity Want in an "Ideal" Primary Care Visit?

August 26th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.